JP Morgan Maintains Overweight on TG Therapeutics, Raises Price Target to $23
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Eric Joseph has maintained an Overweight rating on TG Therapeutics (NASDAQ:TGTX) and raised the price target from $22 to $23.
November 01, 2023 | 7:48 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JP Morgan has maintained an Overweight rating on TG Therapeutics and raised the price target from $22 to $23, which could positively impact the stock.
The Overweight rating maintained by JP Morgan indicates a positive outlook for TG Therapeutics. The increase in price target from $22 to $23 suggests that the analyst sees potential for the stock's price to rise, which could lead to a positive impact on the stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100